**Supplementary Table 2.** Call rate for genotyped SNPs and number of cases, included into analyses of associations with total cholesterol and low-density lipoprotein cholesterol change, baseline carotid intima-media thickness, and its change during rosuvastatin therapy.

|  |  |  |
| --- | --- | --- |
| Gene, SNP | Analysis of associations of SNPs with lipid levels | Analysis of associations of SNPs with CIMT |
| Number of patients genotyped  | Call rate, % | Number of patients with available TC and LDL-C data | Number of patients genotyped  | Call rate, % | Number of patients with available CIMT data |
| Control point of the study, month | Control point of the study, month |
| 1st  | 6th  | 12th  | Baseline\* | 6th  | 12th  |
| *LPA* rs10455872 | 190 | 100 | 190 | 189 | 187 | 116 | 100 | 116 | 113 | 112 |
| *LDLR* rs11672123 | 190 | 100 | 190 | 189 | 187 | 116 | 100 | 116 | 113 | 112 |
| *LDLR* rs6511720 | 190 | 100 | 190 | 189 | 187 | 116 | 100 | 116 | 113 | 112 |
| *APOC1* rs445925 | 111 | 58.1 | 92 | 92 | 92 | 35 | 29.91 | 35 | 35 | 35 |
| *APOE* rs7412 | 144 | 66.36 | 119 | 118 | 116 | 47 | 40.17 | 47 | 44 | 43 |
| *MYLIP* rs6924995 | 190 | 100 | 190 | 189 | 187 | 116 | 100 | 116 | 113 | 112 |
| *MYLIP* rs3757354 | 190 | 100 | 190 | 189 | 187 | 116 | 100 | 116 | 113 | 112 |
| *ABCG2* rs2199936 | 190 | 100 | 190 | 189 | 187 | 116 | 100 | 116 | 113 | 112 |
| *ABCG2* rs1481012 | 190 | 100 | 190 | 189 | 187 | 116 | 100 | 116 | 113 | 112 |
| \* for the patients from group 1 (n=116)SNP indicates single nucleotide polymorphism; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; CIMT, carotid intima-media thickness |